[CrossRef] 29. Baralle, F.E.; Giudice, J. Alternative Splicing as a Regulator of Development and Tissue Identity. Nat. Rev. Mol. Cell Biol. 2017 ,18, 437–451. [CrossRef] [PubMed] 30. Wang, Y.; Zhang, H.; Jiao, B.; Nie, J.; Li, X.; Wang, W.; Wang, H. The Roles of Alternative Splicing in Tumor-Immune Cell Interactions. Curr. Cancer Drug Targets 2020 ,20, 729–740. [CrossRef] 31. Zarling, A.L.; Polefrone, J.M.; Evans, A.M.; Mikesh, L.M.; Shabanowitz, J.; Lewis, S.T.; Engelhard, V .H.; Hunt, D.F. Identification of Class I MHC-Associated Phosphopeptides as Targets for Cancer Immunotherapy. Proc. Natl. Acad. Sci. USA 2006 ,103, 14889–14894. [CrossRef] 32. Malaker, S.A.; Penny, S.A.; Steadman, L.G.; Myers, P .T.; Loke, J.C.; Raghavan, M.; Bai, D.L.; Shabanowitz, J.; Hunt, D.F.; Cobbold, M. Identification of Glycopeptides as Posttranslationally Modified Neoantigens in Leukemia. Cancer Immunol. Res. 2017 ,5, 376–384. [CrossRef] Vaccines 2024 ,12, 717 19 of 24 33. Nejman, D.; Livyatan, I.; Fuks, G.; Gavert, N.; Zwang, Y.; Geller, L.T.; Rotter-Maskowitz, A.; Weiser, R.; Mallel, G.; Gigi, E.; et al. The Human Tumor Microbiome Is Composed of Tumor Type-Specific Intracellular Bacteria. Science 2020 ,368, 973–980.